Phase I study of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] plus Campath [alemtuzumab] (C-CHOP) for the treatment of T-cell, null-cell, and NK cell lymphomas

Trial Profile

Phase I study of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] plus Campath [alemtuzumab] (C-CHOP) for the treatment of T-cell, null-cell, and NK cell lymphomas

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Oct 2008

At a glance

  • Drugs Alemtuzumab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Non-Hodgkin's lymphoma; T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2007 Status change from recruiting to in progress
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top